



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

BIB DATA SHEET

CONFIRMATION NO. 9557

SERIAL NUMBER 10/527,553	FILING or 371(c) DATE 09/09/2005 RULE	CLASS 348	GROUP ART UNIT 1609	ATTORNEY DOCKET NO. ON/4-32678A		
APPLICANTS Paul Dent, Glen Allen, VA; Steven Grant, Richmond, VA; Geoffrey Krystal, Richmond, VA; Chunrong Yu, Rochester, MN;						
** CONTINUING DATA ***** This application is a 371 of PCT/IB03/04053 09/10/2003 which claims benefit of 60/410,286 09/13/2002 and claims benefit of 60/411,344 09/18/2002 (*)Data provided by applicant is not consistent with PTO records.						
** FOREIGN APPLICATIONS *****						
** IF REQUIRED, FOREIGN FILING LICENSE GRANTED **						
Foreign Priority claimed <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No 35 USC 119(a-d) conditions met <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No Verified and Acknowledged <i>[Signature]</i> Examiner's Signature		<input type="checkbox"/> Met after Allowance Initials	STATE OR COUNTRY VA	SHEETS DRAWINGS 0	TOTAL CLAIMS 9	INDEPENDENT CLAIMS 1
ADDRESS NOVARTIS CORPORATE INTELLECTUAL PROPERTY ONE HEALTH PLAZA 104/3 EAST HANOVER, NJ 07936-1080 UNITED STATES						
TITLE Combination of a) n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and b) a histone deacetylase inhibitor for the treatment of leukemia						
FILING FEE RECEIVED 1030	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:			<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Processing Ext. of time) <input type="checkbox"/> 1.18 Fees (Issue) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit		